Vaxcyte, Inc. (NASDAQ:PCVX) Director Teri Loxam Sells 6,250 Shares

Vaxcyte, Inc. (NASDAQ:PCVX) Director Teri Loxam sold 6,250 shares of Vaxcyte stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total value of $531,937.50. Following the completion of the transaction, the director now owns 7,175 shares in the company, valued at $610,664.25. This represents a 46.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Vaxcyte Trading Down 2.9 %

NASDAQ:PCVX opened at $85.30 on Friday. Vaxcyte, Inc. has a twelve month low of $58.10 and a twelve month high of $121.06. The company has a market cap of $10.63 billion, a PE ratio of -18.54 and a beta of 0.98. The company’s 50 day moving average is $88.08 and its two-hundred day moving average is $93.55.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter in the previous year, the business earned ($0.91) EPS. As a group, analysts expect that Vaxcyte, Inc. will post -4.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Janus Henderson Group PLC lifted its holdings in shares of Vaxcyte by 23.1% during the third quarter. Janus Henderson Group PLC now owns 10,921,896 shares of the company’s stock worth $1,247,954,000 after purchasing an additional 2,052,989 shares during the period. RA Capital Management L.P. raised its position in Vaxcyte by 5.9% during the 3rd quarter. RA Capital Management L.P. now owns 8,689,190 shares of the company’s stock worth $992,914,000 after buying an additional 485,436 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Vaxcyte by 47.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,295,837 shares of the company’s stock valued at $148,075,000 after acquiring an additional 419,600 shares during the period. Point72 Asset Management L.P. purchased a new stake in shares of Vaxcyte in the 3rd quarter valued at $41,114,000. Finally, Maverick Capital Ltd. increased its stake in shares of Vaxcyte by 93.7% in the second quarter. Maverick Capital Ltd. now owns 687,908 shares of the company’s stock worth $51,944,000 after acquiring an additional 332,777 shares during the period. 96.78% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have issued reports on PCVX. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $140.00 price objective on shares of Vaxcyte in a research report on Wednesday, November 6th. Finally, The Goldman Sachs Group began coverage on shares of Vaxcyte in a research note on Friday, December 20th. They set a “buy” rating and a $135.00 price objective for the company. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $145.71.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.